GlassScriptPhysician profile
Cynthia A Jansky
NPI 1689789158
$3,393.34
in general payments reported to CMS, 2019-2025
35 companies · $430 in 2025
The $430 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $430 · 2021: $676 · 2022: $613 · 2023: $372 · 2024: $386 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $422.46 | 2019-2023 | |
| Amgen INC. | $267.96 | 2020-2025 | Evenity |
| Biogen, INC. | $252.96 | 2024-2025 | Zurzuvae |
| Novo Nordisk INC | $249.54 | 2019-2024 | Wegovy |
| Exeltis, USA INC. | $237.69 | 2020-2025 | Slynd |
| Intuitive Surgical, INC. | $237.29 | 2019-2023 | Da Vinci Surgical System |
| Astellas Pharma US INC | $226.43 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $213.28 | 2019-2023 | |
| Pfizer INC. | $187.12 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $121.26 | 2022-2025 | |
| Allergan, INC. | $117.15 | 2019-2020 | |
| Coopersurgical, INC. | $97.19 | 2019-2022 | |
| Evofem Biosciences, INC. | $82.54 | 2020-2024 | |
| Boston Scientific Corporation | $62.26 | 2022 | |
| Gynesonics, INC. | $60.55 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $60.15 | 2025 | Gemtesa |
| Avanos Medical | $54.97 | 2020-2023 | On-Q* Pump and Accessories |
| Amag Pharmaceuticals, INC. | $45.19 | 2019-2020 | |
| Avion Pharmaceuticals | $43.63 | 2020-2022 | |
| Millicent US INC | $39.56 | 2025 | Femring, Intrarosa, Femlyv |
| Radius Health, INC. | $36.91 | 2019-2020 | |
| Glaxosmithkline, LLC. | $35.28 | 2019-2022 | |
| Shield Therapeutics INC | $34.98 | 2024 | |
| Merck Sharp & Dohme LLC | $29.84 | 2019-2021 | |
| Agile Therapeutics, INC. | $28.76 | 2022 | |
| Duchesnay USA Incorporated | $23.60 | 2019 | |
| Dexcom, INC. | $22.27 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $17.84 | 2023 | Cologuard Collection Kit |
| Lupin INC. | $15.21 | 2019 | |
| Zyla Life Sciences, INC. | $13.91 | 2020 | |
| Minerva Surgical, INC | $13.69 | 2025 | |
| Therapeuticsmd, INC. | $12.72 | 2021 | |
| Genentech USA, INC. | $12.23 | 2019 | |
| Organon LLC | $10.24 | 2021 | |
| Channel Medsystems, INC. | $6.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Jansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.